In vitro combination between antifungals and diphenyl diselenide against Cryptococcus species. Issue 6 (27th March 2019)

• Record Type: Journal Article
• Authors: Rossato, Luana; Loreto, Erico S.; Venturini, Tarcieli P.; de Azevedo, Maria Isabel; Al‐Hatmi, Abdullah M. S.; Santurio, Janio M.; Alves, Sydney H.
• Is Part Of: Mycoses. Volume 62:Issue 6(2019)
• Page Start: 508
• Page End: 512
• Publication Date: 2019-03-27
• Subjects: amphotericin B -- cryptococcosis -- fluconazole -- flucytosine -- selenium; Pathogenic fungi -- Periodicals; Medical mycology -- Periodicals; 616.969
• DOI: 10.1111/myc.12905
• Languages: English
• ISSNs: 0933-7407

Abstract

Summary: Cryptococcus species are an encapsulated fungal pathogen that cause cryptococcal meningitis. There are limited therapeutic options for this infection. The management includes the use of different antifungals such as amphotericin B, flucytosine, or fluconazole, either alone or in combination. However, numerous therapeutic failures, as well as the limited effectiveness of such therapeutics, have been described. Diphenyl diselenide is a chemically synthesised molecule with was found to have antimicrobial activity. In this study, we evaluated the antifungal activities of fluconazole, amphotericin B and flucytosine, in combination with diphenyl diselenide against 30 clinical isolates of Cryptococcus spp. using CLSI M27‐A3 method and the checkerboard microdilution technique. Our results show that the combination of flucytosine and diphenyl diselenide displayed 100% of synergism. However, when we analysed (PhSe)2 plus AMB or FLZ we observed around 70% of indifference. Our results suggest that the combination of diphenyl diselenide with other antifungal agents deserves attention as a new option for the development of alternative therapies for cryptococcosis.